Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 8, 1999, Pages 2924-2932

  Mitsiades, Nicholas ^a,b,d   Poulaki, Vassiliki ^a   Mastorakos, George ^b   Tseleni Balafouta, Sophia ^c   Kotoula, Vassiliki ^a   Koutras, Demetrios A ^b   Tsokos, Maria ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Evgenidion Hospital   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; FAS ANTIGEN; LIGAND;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 0033346390     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.8.5917     Document Type: Article

References (48)

1. The epidemiology of thyroid disease and implications for screening
2. Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland
3. The prevalence of unsuspected thyroid pathology in 300 sequential autopsies, with special reference to the incidental carcinoma
4. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases
5. Occult thyroid pathology in the young adult: An autopsy study of 138 patients without clinical thyroid disease
6. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies
7. The immune response to papillary thyroid cancer [Editorial]
8. In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer
9. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland
10. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma
11. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome
12. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
13. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
14. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen
15. Cell-autonomous Fas (CD95)/ Fas-ligand interaction mediates activation- induced apoptosis in T-cell hybridomas
16. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
17. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
18. A role for CD95 ligand in preventing graft rejection [published erratum appears in Nature 1998 Jul 9;394(6689):133]
19. Fas ligand-induced apoptosis as a mechanism of immune privilege
20. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
21. Expression of Fas ligand by human cytotrophoblasts: Implications in placentation and fetal survival
22. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
23. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
24. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand
25. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia
26. Fas ligand expression in nodal non-Hodgkin's lymphoma
27. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase
28. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
29. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion?
30. Human lung carcinomas express Fas ligand
31. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis
32. Apoptosis in thyroid diseases: A histochemical study
33. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro
34. Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor
35. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
36. Papillary thyroid carcinomas. Morphology and prognosis
37. Prognostic implications of the tall cell variant of papillary thyroid carcinoma
38. Prognostic factors in differentiated carcinoma of the thyroid gland
39. TUNEL: Improvement and evaluation of the method for in situ apoptotic cell identification
40. Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: Use of a targeted differential RNA display method to select for mRNA subsets
41. Immune evasion by tumours: Involvement of the CD95 (APO-1/Fas) system and its clinical implications
42. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
43. Hashimoto's thyroiditis and carcinoma of the thyroid gland
44. Coexistent carcinoma of the thyroid gland and Hashimoto's thyroiditis
45. Lymphocytic infiltration in thyroid neoplasms. Preliminary prognostic assessments
46. Apoptosis and proliferation in thyroid carcinoma: Correlation with Bcl-2 and p53 protein expression
47. Apoptosis and thyroiditis
48. Constitutive expression of FasL in thyrocytes